The Use of EDX Fluorescence Spectrometry for Pharmaceutical Elemental Impurity Analysis Based on USP<735>
White Paper Jan 06, 2017 | Shimadzu
Shimadzu
New guidelines governing the analysis of elemental impurities in pharmaceuticals are being implemented. Toxic heavy metals and residual metal catalysts may exist in the raw materials of Active Pharmaceutical Ingredients (APIs) or be added during the manufacturing process. These impurities may be a risk to human health.
This white paper demonstrates that X-ray Fluorescence (XRF) is capable of performing elemental impurity analysis of the above 12 elements in various pharmaceutical materials, such as Cellulose, Talc and a Mixture of Cellulose, Talc and TiO2, by the calibration curve method using water solution standard samples, and verifying the qualification of USP <735>.
Related White Papers
Top 10 Factors to Consider When Selecting a Dynamic Light Scattering Instrument
White PaperHere are some questions you should ask yourself as you begin evaluating
dynamic light scattering instruments.
A Closer Look at Cannabis Testing
White PaperThis white paper looks at the findings of a 2014 tour of medicinal marijuana businesses in the State of Oregon where Shimadzu Marketing Managers learned about the key ascpects of the cannabis industry.
READ MOREFive Compelling Reasons to Replace Sieve Analysis with Laser Diffraction
White PaperMalvern Instruments Limited
Switching from sieve analysis to laser diffraction within manufacturing has multiple immediate benefits, the most important of which: time- and cost-savings, better and simpler characterization, better product quality and easier maintenance, are all discussed in this whitepaper.
READ MORETo personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free
LOGIN SUBSCRIBE FOR FREE
